中文名稱:Baohuoside I | 英文名稱:Baohuoside I |
CAS:113558-15-9 | 品牌: 一研 |
保存條件: Store at -20°C | 產(chǎn)品類別: 抑制劑 |
Cas : 113558-15-9 |
產(chǎn)品屬性:
產(chǎn)品名稱 | 規(guī)格 | CAS號(hào) | 型號(hào) |
Baohuoside I | 20mg | 113558-15-9 | EY-Y0165257 |
Cas No.113558-15-9
別名
化學(xué)名 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
分子式 C27H30O10
分子量 514.18
溶解度 DMF: 10 mg/ml,DMSO: 10 mg/ml,Ethanol: 0.5 mg/ml,PBS (pH 7.2): 0.1 mg/ml
儲(chǔ)存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of CXCR4, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity.
Baohuoside I is an inhibitor of CXCR4, and downregulates CXCR4 expression at 12-25 μM. Baohuoside I (0-25 μM) suppresses NF-κB activation in a dose-dependent manner, suppresses CXCL12 induced the invasion of cervical cancer cells. Baohuoside I also inhibits invasion of breast cancer cells[1]. Baohuoside I inhibits A549 cell viability, with IC50s of 25.1 μM at 24 h, 11.5 μM and 9.6 μM at 48 h and 72 h, respectively. Baohuoside I ((25 μM) suppresses the caspase cascade in A549 cells, elevates ROS levels and activates JNK and p38MAPK signaling cascade[2]. Baohuoside I (3.125, 6.25, 12.5, 25.0 and 50.0 μg/mL) significantly and dose-dependently blocks the growth of esophageal squamous cell carcinoma Eca109 cells, with an IC50 of 4.8 μg/mL at 48 h[3].
Baohuoside I (25 mg/kg) decreases β-catenin protein levels, cyclin D1 and survivin expression in nude mice[3].
References:
[1]. Kim B, et al. Baohuoside I suppresses invasion of cervical and breast cancer cells through the downregulation of CXCR4 chemokine receptor expression. Biochemistry. 2014 Dec 9;53(48):7562-9.
[2]. Song J, et al. Reactive oxygen species-mediated mitochondrial pathway is involved in Baohuoside I-induced apoptosis in human non-small cell lung cancer. Chem Biol Interact. 2012 Jul 30;199(1):9-17.
[3]. Wang L, et al. The flavonoid Baohuoside-I inhibits cell growth and downregulates survivin and cyclin D1 expression in esophageal carcinoma via β-catenin-dependent signaling. Oncol Rep. 2011 Nov;26(5):1149-56.
成立日期 | 2014-06-05 (11年) | 注冊(cè)資本 | 100 |
員工人數(shù) | 50-100人 | 年?duì)I業(yè)額 | ¥ 100萬以內(nèi) |
主營行業(yè) | 生化試劑,抗體,細(xì)胞培養(yǎng),分子生物學(xué),免疫安全 | 經(jīng)營模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP6年
|
成都彼樣生物科技有限公司
|
2025-01-10 | |
詢價(jià) |
VIP12年
|
成都瑞芬思德丹生物科技有限公司
|
2025-01-10 | |
¥280 |
VIP1年
|
湖北萃園生物科技有限公司
|
2025-01-10 | |
¥450 |
VIP6年
|
成都格利普生物科技有限公司
|
2025-01-10 | |
¥900 |
VIP13年
|
南京春秋生物工程有限公司
|
2025-01-07 | |
詢價(jià) |
VIP7年
|
南京道斯夫生物科技有限公司
|
2024-12-28 | |
詢價(jià) |
中國食品藥品檢定研究院
|
2024-12-25 | ||
¥500 |
VIP13年
|
上海融禾醫(yī)藥科技發(fā)展有限公司
|
2024-12-15 | |
¥283 |
VIP12年
|
上海陶術(shù)生物科技有限公司
|
2024-12-02 | |
¥774.90 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 |